Oxford BioDynamics

Oxford BioDynamics Plc (AIM: OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship product, EpiSwitch CiRT, predicts how a patient will respond to immune checkpoint inhibitor therapies. OBD's proprietary EpiSwitch® platform harnesses 3D genomic regulation biomarkers to develop molecular diagnostic classifiers for numerous indications, including predicting response to therapy, patient prognosis, disease diagnosis, and residual disease monitoring.



Answer ALS

Answer ALS is the single largest & most comprehensive ALS research project in history, producing more ALS data than has ever been amassed, while openly sharing with the global research community. The program coordinates with over 20 institutions, establishing a critical foundation for new clinical trials and developing new ways to categorize ALS patients to identify specific druggable pathways in an effort to make ALS a treatable disease. Since opening the Answer ALS data repository, Neuromine, in 2021, over 300 independent ALS research projects have begun worldwide from free access to the rich data and available samples.




bit.bio combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines. Our precision cell programming technology opti-oxTM enables deterministic activation of TF codes to program new cell identities including neurodegenerative disorders such as Gaucher’s, Huntington’s and Parkinson’s disease. opti-ox reprogramming overcomes the ultimate barriers of cell manufacturing and enables precise, rapid and scalable generation of pure human cell types.



PRC Clinical

PRC Clinical is the CRO of choice for ALS trials, providing specialty CRO services for over 20 years. Our innovative approach to executing studies combines cutting-edge technology with extensive experience and deep therapeutic knowledge. PRC Clinical delivers strategic solutions and high-touch approaches that ensure patients get the support they need to remain engaged and enrolled throughout your trial. Along with our host of online management tools, we ensure your trial receives the TLC it deserves from PRC.



Neuro-Sys is a leading contract research firm specializing in in vitro and in vivo studies for neurodegenerative diseases. Our expertise in pharmacology and biomolecular analysis offers deep insights into compound mechanisms. Combined with advanced techniques such as stereotaxic injections and behavioral analyses, we provide comprehensive evaluations of therapeutics. Our studies enable companies to construct a holistic narrative about screened compounds, facilitating informed decision-making in drug development. Backed by a team of experienced neuropharmacologists and physicians, we deliver reliable results through research, cutting-edge technology, and customized platforms. Our commitment to excellence in output and superior customer service ensures streamlined results and builds lasting trust with our partners.



BrainXell provides high-purity, iPSC-derived human neurons and glia for research and development with a focus on drug discovery. Utilizing proprietary technology, we generate high-purity, subtype-specific neurons that mature rapidly and are quickly and easily ready for a variety of assays. Multiple neuron subtypes relevant to a range of disorders are available. Additionally, each neuron subtype can be made in custom batches from 50 million to 10 billion neurons from unique iPSC lines. We are dedicated to delivering the highest quality products for off-the-shelf neurons and custom service projects.





Inoviv is an LC-MS proteomics services company providing end-to-end quantitative biomarker solutions to biotech, pharma, and academia for all stages of drug development. With decades of experience validating discovery and targeted LC-MS proteomics workflows, our LC-MS assays demonstrate exceptional throughput and specificity fit for regulatory submission. We offer custom designed and pre-validated IP-MS and LC-MS assays expertly curated to elucidate treatment efficacy, target engagement and MoA, quantify different proteoforms, and facilitate patient selection in a wide range of tissue and biofluid samples. Current solutions support work in neurodegenerative diseases, such as Parkinson’s, Alzheimer’s, ALS, and beyond.



Atlantic Research Group

ARG is a contract research organization focused on oncology, immunology, and neurology, providing comprehensive clinical program development services ranging from planning to commercialization, achieving over 50 market authorizations to date. Founded in 2004 with the vision that every project should be highly individualized, ARG has experienced consistent growth across the globe, expanding our range to include drug and device strategic consulting, clinical trial management services, as well as clinical data and analytic solutions. ARG uses first-in-class technology platforms along with relationship-driven flexibility to optimize clinical studies because we believe everyone deserves to be well.



With more than 35 products launched in over 60 countries, the Zydis® ODT (orally disintegrating tablet) fast-dissolve technology continues to be the world’s best-in-class ODT technology. The Zydis fast-dissolve platform consists of three technologies: Zydis ODT, Zydis Ultra, and Zydis Bio. Zydis ODT is a unique freeze-dried dosage form that disperses within three seconds without the need for water. Zydis Ultra technology offers enhanced taste-masking capabilities, increased drug loading, and the potential for functional coating. Zydis Bio technology offers a formulation strategy for oral delivery of peptides, allergens, and viral vaccines.



PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments and reduce the attrition rate in clinical development. Our capabilities include behavioral testing, surgical models, electrophysiology, translational EEG, quantitative histology, biomarker analysis, bioanalysis and microdialysis. We offer a variety of validated mouse models including in-licensed transgenic models that support research in areas such as amyotrophic lateral sclerosis, Alzheimer's disease, Huntington’s disease, Parkinson’s disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy and a broad array of pain models.


Unlearn Ai

Unlearn is a San Francisco-based technology company pioneering generative machine learning methods to eliminate trial and error in medicine. Unlearn’s technology using patient digital twins is regulatory-qualified and used by leading global pharmaceutical companies to run AI-powered clinical trials that reach full enrollment faster and bring new treatments to patients sooner.


Sano Genetics

Sano combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrolment and simplifying operations for precision medicine teams driving breakthroughs for patients.


Want to see your logo here?